Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry.

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J
Clin 2008;58:71–96.
2. Wilkins MR, Appel RD, Van Eyk JE, et al. Guidelines for the next
10 years of proteomics. Proteomics 2006;6:4–8.
3. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine
signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:
1190–1203.
4. Syka JE, Coon JJ, Schroeder MJ, et al. Peptide and protein sequence
analysis by electron transfer dissociation mass spectrometry. Proc Natl
Acad Sci U S A 2004;101:9528–9533.
5. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and
treatment selection. Nat Rev Cancer 2005;5:845–856.
6. Sidransky D, Irizarry R, Califano JA, et al. Serum protein maldi profiling
to distinguish upper aerodigestive tract cancer patients from control
subjects. J Natl Cancer Inst 2003;95:1711–1717.
7. Villanueva J, Philip J, Entenberg D, et al. Serum peptide profiling by
magnetic particle-assisted, automated sample processing and maldi-tof
mass spectrometry. Anal Chem 2004;76:1560–1570.
8. Zimmerman LJ, Wernke GR, Caprioli RM, et al. Identification of
protein fragments as pattern features in maldi-ms analyses of serum. J
Proteome Res 2005;4(5):1672–1680.
9. Mobley JA, Lam YW, Lau KM, et al. Monitoring the serological proteome:
The latest modality in prostate cancer detection. J Urol 2004;
172:331–337.
10. Yildiz PB, Shyr Y, Rahman JS, et al. Diagnostic accuracy of maldi mass
spectrometric analysis of unfractionated serum in lung cancer. J Thorac
Oncol 2007;2:893–901.
11. M’Koma AE, Blum DL, Norris JL, et al. Detection of pre-neoplastic
and neoplastic prostate disease by maldi profiling of urine. Biochem
Biophys Res Commun 2007;353:829–834.
12. Rahman SM, Shyr Y, Yildiz PB, et al. Proteomic patterns of preinvasive
bronchial lesions. Am J Respir Crit Care Med 2005;172:1556–1562.
13. Yanagisawa K, Xu BJ, Carbone DP, et al. Molecular fingerprinting in
human lung cancer. Clin Lung Cancer 2003;5:113–118.
14. Amann JM, Chaurand P, Gonzalez A, et al. Selective profiling of proteins
in lung cancer cells from fine-needle aspirates by matrix-assisted laser
desorption ionization time-of-flight mass spectrometry. Clin Cancer Res
2006;12:5142–5150.
15. Xu BJ, Caprioli RM, Sanders ME, et al. Direct analysis of laser capture
microdissected cells by maldi mass spectrometry. J Am Soc Mass
Spectrom 2002;13:1292–1297.
16. Anderson NL, Anderson NG. The human plasma proteome: history,
character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845–867.
17. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence
of tamoxifen-treated, node-negative breast cancer. N Engl J Med
2004;351:2817–2826.
18. van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature
as a predictor of survival in breast cancer. N Engl J Med 2002;
347:1999–2009.
19. Zhu H, Snyder M. Protein arrays and microarrays. Curr Opin Chem
Biol 2001;5:40–45.
20. Madoz-Gurpide J, Wang H, Misek DE, et al. Protein based microarrays:
a tool for probing the proteome of cancer cells and tissues.
Proteomics 2001;1:1279–1287.
21. Zhong L, Hidalgo GE, Stromberg AJ, et al. Using protein microarray
as a diagnostic assay for non-small cell lung cancer. Am J Respir Crit
Care Med 2005;172:1308–1314.
22. Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein
microarrays which capture disease progression show activation of prosurvival
pathways at the cancer invasion front. Oncogene 2001;20:
1981–1989.
23. Bjorling E, Lindskog C, Oksvold P, et al. A web-based tool for in silico
biomarker discovery based on tissue-specific protein profiles in normal
and cancer tissues. Mol Cell Proteomics 2008;7:825–844.
24. Omenn GS. Strategies for plasma proteomic profiling of cancers.
Proteomics 2006;6:5662–5673.
25. Anderson NL, Polanski M, Pieper R, et al. The human plasma proteome:
A nonredundant list developed by combination of four separate
sources. Mol Cell Proteomics 2004;3:311–326.
26. Keshishian H, Addona T, Burgess M, et al. Quantitative, multiplexed
assays for low abundance proteins in plasma by targeted mass spectrometry
and stable isotope dilution. Mol Cell Proteomics 2007;6:
2212–2229.
27. Stahl-Zeng J, Lange V, Ossola R, et al. High sensitivity detection of
plasma proteins by multiple reaction monitoring of n-glycosites. Mol
Cell Proteomics 2007;6:1809–1817.
28. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction
monitoring assays for major plasma proteins. Mol Cell Proteomics
2006;5:573–588.
29. Yates JR III, Gilchrist A, Howell KE, et al. Proteomics of organelles and
large cellular structures. Nat Rev Mol Cell Biol 2005;6:702–714.
30. Forner F, Foster LJ, Campanaro S, et al. Quantitative proteomic comparison
of rat mitochondria from muscle, heart, and liver. Mol Cell
Proteomics 2006;5:608–619.
31. Omenn GS, States DJ, Adamski M, et al. Overview of the hupo
plasma proteome project: results from the pilot phase with 35 collaborating
laboratories and multiple analytical groups, generating a core
dataset of 3020 proteins and a publicly-available database. Proteomics
2005;5:3226–3245.
32. Peng J, Elias JE, Thoreen CC, et al. Evaluation of multidimensional
chromatography coupled with tandem mass spectrometry (lc/lc-ms/ms)
for large-scale protein analysis: the yeast proteome. J Proteome Res
2003;2:43–50.
33. Yi EC, Marelli M, Lee H, et al. Approaching complete peroxisome
characterization by gas-phase fractionation. Electrophoresis 2002;23:
3205–3216.
34. Blonder J, Yu LR, Radeva G, et al. Combined chemical and enzymatic
stable isotope labeling for quantitative profiling of detergent-insoluble
membrane proteins isolated using triton x-100 and brij-96. J Proteome
Res 2006;5:349–360.
35. Tian Q, Stepaniants SB, Mao M, et al. Integrated genomic and proteomic
analyses of gene expression in mammalian cells. Mol Cell
Proteomics 2004;3:960–969.
36. Yan W, Lee H, Deutsch EW, et al. A dataset of human liver proteins
identified by protein profiling via isotope-coded affinity tag (icat) and
tandem mass spectrometry. Mol Cell Proteomics 2004;3:1039–1041.
37. Brand M, Ranish JA, Kummer NT, et al. Dynamic changes in transcription
factor complexes during erythroid differentiation revealed by
quantitative proteomics. Nat Struct Mol Biol 2004;11:73–80.
38. Old WM, Meyer-Arendt K, Aveline-Wolf L, et al. Comparison of labelfree
methods for quantifying human proteins by shotgun proteomics.
Mol Cell Proteomics 2005;4:1487–1502.
39. Ono M, Shitashige M, Honda K, et al. Label-free quantitative proteomics
using large peptide data sets generated by nano-flow liquid chromatography
and mass spectrometry. Mol Cell Proteomics 2006;5:1338–1347.
40. Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumour subsets
in non–small-cell lung cancer. Lancet 2003;362:433–439.
41. Yamagata N, Shyr Y, Yanagisawa K, et al. A training-testing approach
to the molecular classification of resected non-small cell lung cancer.
Clin Cancer Res 2003;9:4695–4704.
42. Tukey JW. Tightening the clinical trial. Control Clin Trials 1993;14:
266–285.
43. Shyr Y, Kim K. Weighted flexible compound covariate method for
classifying microarray data. In: Berrar D, ed. A Practical Approach to
Microarray Data Analysis. New York: Kluwer Academic, 2003:186–200.
44. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in
hereditary breast cancer. N Engl J Med 2001;344:539–548.
45. Wardwell NR, Massion PP. Novel strategies for the early detection and
prevention of lung cancer. Semin Oncol 2005;32:259–268.
46. Sullivan PM, Etzioni R, Feng Z, et al. Phases of biomarker development
for early detection of cancer. J Natl Cancer Inst 2001;93:1054–1061.
47. Chanin TD, Merrick DT, Franklin WA, et al. Recent developments in
biomarkers for the early detection of lung cancer: perspectives based on
publications 2003 to present. Curr Opin Pulm Med 2004;10:242–247.
48. Chen G, Gharib TG, Huang CC, et al. Proteomic analysis of lung
adenocarcinoma: Identification of a highly expressed set of proteins in
tumors. Clin Cancer Res 2002;8:2298–2305.
49. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled
with a pattern-matching algorithm distinguishes prostate cancer from
benign prostate hyperplasia and healthy men. Cancer Res 2002;62:
3609–3614.
50. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns
in serum to identify ovarian cancer. Lancet 2002;359:572–577.
51. Petricoin EF, 3rd, Ornstein DK, Paweletz CP, et al. Serum proteomic
patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94:
1576–1578.
52. Yang SY, Xiao XY, Zhang WG, et al. Application of serum seldi proteomic
patterns in diagnosis of lung cancer. BMC Cancer 2005;5:83.
53. Baggerly KA, Morris JS, Coombes KR. Reproducibility of seldi-tof
protein patterns in serum: Comparing datasets from different experiments.
Bioinformatics 2004;20:777–785.
54. Baggerly KA, Morris JS, Edmonson SR, et al. Signal in noise: evaluating
reported reproducibility of serum proteomic tests for ovarian
cancer. J Natl Cancer Inst 2005;97:307–309.
55. Coombes KR, Morris JS, Hu J, et al. Serum proteomics profiling—a
young technology begins to mature. Nat Biotechnol 2005;23:291–292.
56. Koomen JM, Li D, Xiao LC, et al. Direct tandem mass spectrometry
reveals limitations in protein profiling experiments for plasma biomarker
discovery. J Proteome Res 2005;4:972–981.
57. Marshall J, Kupchak P, Zhu W, et al. Processing of serum proteins
underlies the mass spectral fingerprinting of myocardial infarction.
J Proteome Res 2003;2:361–372.
58. Howard BA, Wang MZ, Campa MJ, et al. Identification and validation
of a potential lung cancer serum biomarker detected by matrix-assisted
laser desorption/ionization-time of flight spectra analysis. Proteomics
2003;3:1720–1724.
59. Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities
confer tumor-specific serum peptidome patterns. J Clin Invest
2006;116:271–284.
60. Gharib TG, Chen G, Wang H, et al. Proteomic analysis of cytokeratin
isoforms uncovers association with survival in lung adenocarcinoma.
Neoplasia 2002;4:440–448.
61. Chen G, Wang H, Miller CT, et al. Reduced selenium-binding
protein 1 expression is associated with poor outcome in lung adenocarcinomas.
J Pathol 2004;202:321–329.
62. Li C, Xiao Z, Chen Z, et al. Proteome analysis of human lung squamous
carcinoma. Proteomics 2006;6:547–558.
63. Moon EY, Song JH, Yang KH. Actin-sequestering protein, thymosinbeta-
4 (tb4), inhibits caspase-3 activation in paclitaxel-induced tumor
cell death. Oncol Res 2007;16:507–516.
64. Oh JM, Ryoo IJ, Yang Y, et al. Hypoxia-inducible transcription factor
(hif )-1 alpha stabilization by actin-sequestering protein, thymosin
beta-4 (tb4) in hela cervical tumor cells. Cancer Lett 2008;264:29–35.
65. Brieger A, Plotz G, Zeuzem S, et al. Thymosin beta 4 expression and
nuclear transport are regulated by hmlh1. Biochem Biophys Res Commun
2007;364:731–736.
66. Anderson DD, Woeller CF, Stover PJ. Small ubiquitin-like modifier-1
(sumo-1) modification of thymidylate synthase and dihydrofolate reductase.
Clin Chem Lab Med 2007;45:1760–1763.
67. Chung V, Zhou B, Liu X, et al. Sumoylation plays a role in gemcitabine-
and bortezomib-induced cytotoxicity in human oropharyngeal
carcinoma kb gemcitabine-resistant clone. Mol Cancer Ther 2006;5:
533–540.
68. Kang JS, Saunier EF, Akhurst RJ, et al. The type i tgf-beta receptor is
covalently modified and regulated by sumoylation. Nat Cell Biol 2008;
10:654–664.
69. Miyazono K, Kamiya Y, Miyazawa K. Sumo amplifies tgf-beta signalling.
Nat Cell Biol 2008;10:635–637.
70. Seeler JS, Bischof O, Nacerddine K, et al. Sumo, the three rs and
cancer. Curr Top Microbiol Immunol 2007;313:49–71.
71. Yanagisawa K, Tomida S, Shimada Y, et al. A 25-signal proteomic
signature and outcome for patients with resected non-small-cell lung
cancer. J Natl Cancer Inst 2007;99:858–867.
72. Jacot W, Lhermitte L, Dossat N, et al. Serum proteomic profiling of
lung cancer in high-risk groups and determination of clinical outcomes.
J Thorac Oncol 2008;3:840–850.
73. Maeda J, Hirano T, Ogiwara A, et al. Proteomic analysis of stage I primary
lung adenocarcinoma aimed at individualisation of postoperative
therapy. Br J Cancer 2008;98:596–603.
74. Fujii T, Toyooka S, Ichimura K, et al. Ercc1 protein expression predicts
the response of cisplatin-based neoadjuvant chemotherapy in nonsmall-
cell lung cancer. Lung Cancer 2008;59:377–384.
75. Scagliotti GV, Parikh P, von Pawel J, et al. Phase iii study comparing
cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-
naive patients with advanced-stage non-small-cell lung cancer.
J Clin Oncol 2008;26:3543–3551.
76. Dowlati A, Gray R, Sandler AB, et al. Cell adhesion molecules, vascular
endothelial growth factor, and basic fibroblast growth factor in patients
with non-small cell lung cancer treated with chemotherapy with or
without bevacizumab—an eastern cooperative oncology group study.
Clin Cancer Res 2008;14:1407–1412.
77. Norden-Zfoni A, Desai J, Manola J, et al. Blood-based biomarkers of
su11248 activity and clinical outcome in patients with metastatic imatinib-
resistant gastrointestinal stromal tumor. Clin Cancer Res 2007;13:
2643–2650.
78. Tran HT, Kim ES, Lee JJ, et al. Correlation between plasma cytokine/
angiogenic factors (c/af ) and signaling pathways activation from
baseline tumor biopsy specimens in patients with advanced non small
cell lung cancer (nsclc): preliminary analysis from the biomarker-based
approaches of targeted therapy for lung cancer elimination (battle)
clinical study. 2008 ASCO Annual Meeting . Chicago, IL, 2008.
abstract 8010.
79. Grote T, Siwak DR, Fritsche HA, et al. Validation of reverse phase
protein array for practical screening of potential biomarkers in serum
and plasma: accurate detection of ca19-9 levels in pancreatic cancer.
Proteomics 2008;8:3051–3060.
80. Murphy L, Clynes M, Keenan J. Proteomic analysis to dissect mitoxantrone
resistance-associated proteins in a squamous lung carcinoma.
Anticancer Res 2007;27:1277–1284.
81. Murphy L, Henry M, Meleady P, et al. Proteomic investigation of taxol
and taxotere resistance and invasiveness in a squamous lung carcinoma
cell line. Biochim Biophys Acta 2008;1784(9):1184–1191.
82. Chen G, Li A, Zhao M, et al. Proteomic analysis identifies protein targets
responsible for depsipeptide sensitivity in tumor cells. J Proteome
Res 2008;7:2733–2742.
83. Okano T, Kondo T, Fujii K, et al. Proteomic signature corresponding
to the response to gefitinib (iressa, zd1839), an epidermal growth factor
receptor tyrosine kinase inhibitor in lung adenocarcinoma. Clin Cancer
Res 2007;13:799–805.
84. Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify
non-small-cell lung cancer patients for clinical outcome after treatment
with epidermal growth factor receptor tyrosine kinase inhibitors:
a multicohort cross-institutional study. J Natl Cancer Inst 2007;99:
838–846.